secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2022-12-29T23:59:59+00:00
Accession:  0001104659-22-130714
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports FY2022 net loss $66.1M; raises ~$55M; PDUFA date Aug 29, 2023
--------------------------------------------------------------------------------

- Net loss $66.1M ($0.31/sh) for FY2022 vs $53.2M ($0.35/sh) in FY2021.
- Cash and equivalents $17.4M at Sept 30, 2022; subsequent financings raised ~$55M gross.
- FDA accepted BLA for ONS-5010; PDUFA goal date set for August 29, 2023.
- Entered strategic commercialization agreement with AmerisourceBergen for 3PL and services.
- Appointed Julia Haller, MD to the Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465922130714/0001104659-22-130714-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465922130714/tm2233528d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-130714

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer